SCHEMBL4286154

SCHEMBL4286154

OC(=S)c1ccc(O)c(O)c1-c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.38
SELL P14151 1/20 0.38
SELP P16109 1/20 0.38
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
RECQL P46063 2/20 0.37
GAA P10253 2/20 0.37
POLB P06746 1/20 0.37
PKM P14618 1/20 0.37
PDE4B Q07343 3/20 0.37
PDE4A P27815 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37
BACE1 P56817 1/20 0.37
HNF4A P41235 3/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
HSD17B10 Q99714 3/20 0.36
MCL1 Q07820 2/20 0.36
ACMSD Q8TDX5 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8976015 0.83 MAPT (0.42) KDM4EMAPTGAAPDE4BPDE4A
SCHEMBL7026199 0.80 SELL (0.57) SELLSELPKDM4EHNF4AALDH1A1
SCHEMBL31509453 0.80 SELL (0.57) SELLSELPKDM4EHNF4AALDH1A1
SCHEMBL31275930 0.78 ALOX5 (0.46) ALOX5KDM4EMAPTRECQLGAA
SCHEMBL9348187 0.78 ALOX5 (0.46) ALOX5KDM4EMAPTRECQLGAA
SCHEMBL7426449 0.77 BCAT2 (0.48) SELLSELPKDM4EMAPTHNF4A
SCHEMBL1286775 0.76 MEN1 (0.51) KDM4EMAPTGAAPDE4APDE4D
SCHEMBL949284 0.72 BACE1 (0.52) ALOX5KDM4EMAPTRECQLGAA
SCHEMBL27557303 0.71 HSD17B10 (0.50) ALOX5KDM4EMAPTRECQLGAA
SCHEMBL27485021 0.71 KDM4E (0.46) ALOX5KDM4EMAPTRECQLGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9061006-B2 Compositions and methods for diagnosing and treating phenylketonuria (PKU) RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2015-06-23 US disclosed
US-20130344079-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PHENYLKETONURIA (PKU) RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2013-12-26 US disclosed
EP-1663199-B1 COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES UNIV TEL AVIV FUTURE TECH DEV (IL) 2013-04-03 EP disclosed
US-20130078233-A1 COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) 2013-03-28 US disclosed
US-8372880-B2 Compositions and methods using same for treating amyloid-associated diseases TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) 2013-02-12 US disclosed
WO-2012120518-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PHENYLKETONURIA (PKU) RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) 2012-09-13 WO disclosed
US-20090156471-A1 Use of anti-amyloid agents for treating and typing pathogen infections RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2009-06-18 US disclosed
US-20060194777-A1 Compositions and methods using same for treating amyloid-associated diseases TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) 2006-08-31 US disclosed
EP-1663199-A1 COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES Tel Aviv University Future Technology Development L.P. (IL) 2006-06-07 EP disclosed
WO-2006006172-A2 USE OF ANTI-AMYLOID AGENTS FOR TREATING AND TYPING PATHOGEN INFECTIONS RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) 2006-01-19 WO disclosed
WO-2005027901-A1 COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES TEL AVIV UNIVERSITY FUTURE TECHNOLOGY DEVELOPMENT L.P. (IL) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194777-A1 Compositions and methods using same for treating amyloid-associated diseases APP, PSEN2, PSEN1 ALOX5 468/4885SELL 4797/4885SELP 1381/4885
US-20090156471-A1 Use of anti-amyloid agents for treating and typing pathogen infections TTR, HLA-DRB1, SERPINA3 ALOX5 1001/4885SELL 1854/4885SELP 72/4885
US-20130344079-A1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING PHENYLKETONURIA (PKU) PAH, PDXK, TTR ALOX5 3622/4885SELL 4362/4885SELP 1590/4885
US-20130078233-A1 COMPOSITIONS AND METHODS USING SAME FOR TREATING AMYLOID-ASSOCIATED DISEASES APP, PSEN2, PSEN1 ALOX5 468/4885SELL 4797/4885SELP 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.